Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant dabrafenib + trametinib after complete resection of stage III BRAF V600-mutant melanoma in Chinese patients
CTR20200504Phase 4Active
- Sponsor
- Novartis
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dabrafenib + trametinib, trametinib in melanoma, mucosal melanoma (MM), cutaneous melanoma (CM), sponsored by Novartis. Started Dec 2020; status: active.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanomamucosal melanoma (MM)cutaneous melanoma (CM)
Beyond the preview
Go deeper on CTR20200504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200504.